Boehringer Ingelheim
Coverage of Boehringer Ingelheim in the Nexus archive.
- Evolving Landscape for Managing Cardiovascular, Renal and Metabolic Conditions
Boehringer Ingelheim executives Brian Hilberdink and Neerja Balachander discuss key developments in managing cardiovascular, renal, and metabolic conditions. The focus is on the evolving landscape of these medical areas.
- STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
Boehringer Ingelheim's obesity drug survodutide showed 13% weight loss in a Phase 3 trial, lower than Novo Nordisk's Wegovy and Eli Lilly's Zepbound. While the drug reduced liver fat by 63%, it appears less efficacious and tolerable compared to existing treatments.
- STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more
Eli Lilly is reducing its $2.67 billion investment in Germany's weight-loss syringe production due to new cost-cutting laws, and Boehringer Ingelheim is cutting $1 billion in German investments amid sector uncertainty. U.S. FDA Acting Commissioner Kyle Diamantas is engaging rare disease groups to address concerns raised by his predecessor's policies.
- STAT+: Supreme Court rejects challenge to Medicare drug price negotiation
The Supreme Court rejected a challenge to the Medicare drug price negotiation program, declining to take up lawsuits from several pharmaceutical companies. The decision is a blow to the brand drug industry's legal campaign against the program. The court did not provide a reason for its decision.